Loading...

Pharmacy Chain 36.6

MISX:APTK
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
APTK
MISX
RUB12B
Market Cap
  1. Home
  2. RU
  3. Consumer Retailing
Company description

Public Joint-Stock Company Pharmacy Chain 36.6 operates pharmacies in Russia. The last earnings update was 206 days ago. More info.


Add to Portfolio Compare Print
APTK Share Price and Events
7 Day Returns
0.9%
MISX:APTK
1.5%
Europe Consumer Retailing
0.4%
RU Market
1 Year Returns
-35.8%
MISX:APTK
6.3%
Europe Consumer Retailing
1.3%
RU Market
APTK Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Pharmacy Chain 36.6 (APTK) 0.9% -4.1% 7.9% -35.8% -70.3% -65.3%
Europe Consumer Retailing 1.5% 0.6% 9.9% 6.3% -3.9% -8.9%
RU Market 0.4% -1.2% 6.2% 1.3% 32.4% 85.5%
1 Year Return vs Industry and Market
  • APTK underperformed the Consumer Retailing industry which returned 6.3% over the past year.
  • APTK underperformed the Market in Russian Federation which returned 1.3% over the past year.
Price Volatility
APTK
Industry
5yr Volatility vs Market
Related Companies

APTK Value

 Is Pharmacy Chain 36.6 undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Pharmacy Chain 36.6 is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Pharmacy Chain 36.6 has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Pharmacy Chain 36.6. This is due to cash flow or dividend data being unavailable. The share price is RUB5.04.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Pharmacy Chain 36.6's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Pharmacy Chain 36.6's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
MISX:APTK PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in RUB RUB-6.73
MISX:APTK Share Price ** MISX (2019-03-22) in RUB RUB5.04
Europe Consumer Retailing Industry PE Ratio Median Figure of 33 Publicly-Listed Consumer Retailing Companies 19.9x
Russian Federation Market PE Ratio Median Figure of 131 Publicly-Listed Companies 7.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Pharmacy Chain 36.6.

MISX:APTK PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= MISX:APTK Share Price ÷ EPS (both in RUB)

= 5.04 ÷ -6.73

-0.75x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pharmacy Chain 36.6 is loss making, we can't compare its value to the Europe Consumer Retailing industry average.
  • Pharmacy Chain 36.6 is loss making, we can't compare the value of its earnings to the Russian Federation market.
Price based on expected Growth
Does Pharmacy Chain 36.6's expected growth come at a high price?
Raw Data
MISX:APTK PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.75x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Consumer Retailing Industry PEG Ratio Median Figure of 25 Publicly-Listed Consumer Retailing Companies 1.26x
Russian Federation Market PEG Ratio Median Figure of 31 Publicly-Listed Companies 0.62x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Pharmacy Chain 36.6, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Pharmacy Chain 36.6's assets?
Raw Data
MISX:APTK PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in RUB RUB-8.10
MISX:APTK Share Price * MISX (2019-03-22) in RUB RUB5.04
Europe Consumer Retailing Industry PB Ratio Median Figure of 41 Publicly-Listed Consumer Retailing Companies 1.55x
Russian Federation Market PB Ratio Median Figure of 151 Publicly-Listed Companies 0.83x
MISX:APTK PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= MISX:APTK Share Price ÷ Book Value per Share (both in RUB)

= 5.04 ÷ -8.10

-0.62x

* Primary Listing of Pharmacy Chain 36.6.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pharmacy Chain 36.6 has negative assets, we can't compare the value of its assets to the Europe Consumer Retailing industry average.

Next steps:

  1. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Pharmacy Chain 36.6's regulatory filings and announcements.
  2. Show me more potentially undervalued companies in the Consumer Retailing industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Pharmacy Chain 36.6's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Consumer Retailing industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Consumer Retailing industry average (and greater than 0)? (1 check)
  5. Pharmacy Chain 36.6 has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

APTK Future Performance

 How is Pharmacy Chain 36.6 expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pharmacy Chain 36.6 has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.5%
Expected Consumer Retailing industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Pharmacy Chain 36.6 expected to grow at an attractive rate?
  • Unable to compare Pharmacy Chain 36.6's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Pharmacy Chain 36.6's earnings growth to the Russian Federation market average as no estimate data is available.
  • Unable to compare Pharmacy Chain 36.6's revenue growth to the Russian Federation market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
MISX:APTK Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Consumer Retailing Industry Earnings Growth Rate Market Cap Weighted Average 13.5%
Europe Consumer Retailing Industry Revenue Growth Rate Market Cap Weighted Average 3.8%
Russian Federation Market Earnings Growth Rate Market Cap Weighted Average 3.6%
Russian Federation Market Revenue Growth Rate Market Cap Weighted Average 4.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
MISX:APTK Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (8 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in RUB Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
MISX:APTK Past Financials Data
Date (Data in RUB Millions) Revenue Cash Flow Net Income *
2018-06-30 48,191 -12,089 -15,683
2018-03-31 48,222 -11,612 -14,390
2017-12-31 48,253 -11,134 -13,097
2017-09-30 46,077 -9,807 -13,891
2017-06-30 45,914 -8,439 -11,859
2017-03-31 45,931 -5,961 -10,602
2016-12-31 45,947 -3,483 -9,345
2016-09-30 42,217 -698 -4,875
2016-06-30 38,487 2,088 -404
2016-03-31 35,189 2,947 -291
2015-12-31 31,890 3,806 -178

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Pharmacy Chain 36.6 is high growth as no earnings estimate data is available.
  • Unable to determine if Pharmacy Chain 36.6 is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
MISX:APTK Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (8 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Pharmacy Chain 36.6 Company Filings, last reported 8 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

MISX:APTK Past Financials Data
Date (Data in RUB Millions) EPS *
2018-06-30 -6.73
2018-03-31 -6.17
2017-12-31 -5.62
2017-09-30 -6.91
2017-06-30 -7.01
2017-03-31 -7.84
2016-12-31 -9.22
2016-09-30 -4.91
2016-06-30 -0.42
2016-03-31 -0.30
2015-12-31 -0.19

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Pharmacy Chain 36.6 will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Pharmacy Chain 36.6's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Consumer Retailing companies here
  2. Pharmacy Chain 36.6's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Pharmacy Chain 36.6's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Pharmacy Chain 36.6 has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

APTK Past Performance

  How has Pharmacy Chain 36.6 performed over the past 5 years?

  • Pharmacy Chain 36.6's last earnings update was 206 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Pharmacy Chain 36.6's growth in the last year to its industry (Consumer Retailing).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Pharmacy Chain 36.6 does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Pharmacy Chain 36.6's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Pharmacy Chain 36.6's 1-year growth to the Europe Consumer Retailing industry average as it is not currently profitable.
Earnings and Revenue History
Pharmacy Chain 36.6's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Pharmacy Chain 36.6 Company Filings, last reported 8 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

MISX:APTK Past Revenue, Cash Flow and Net Income Data
Date (Data in RUB Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 48,191.00 -15,683.00 13,852.00
2018-03-31 48,222.00 -14,390.00 14,144.50
2017-12-31 48,253.00 -13,097.00 14,437.00
2017-09-30 46,076.50 -13,891.00 16,934.50
2017-06-30 45,914.00 -11,859.00 17,379.00
2017-03-31 45,930.50 -10,602.00 15,974.00
2016-12-31 45,947.00 -9,345.00 14,569.00
2016-09-30 42,217.00 -4,874.50 12,455.00
2016-06-30 38,487.00 -404.00 10,341.00
2016-03-31 35,188.50 -291.00 9,648.00
2015-12-31 31,890.00 -178.00 8,955.00
2015-06-30 24,534.00 416.00 6,442.00
2015-03-31 21,802.50 88.00 5,945.50
2014-12-31 19,071.00 -240.00 5,449.00
2014-06-30 10,179.00 -8,108.00 3,730.00
2014-03-31 6,535.00 -9,546.50 3,349.00
2013-12-31 6,231.00 -9,637.00 3,502.00
2013-06-30 10,574.00 -2,963.00 3,344.00
2013-03-31 20,405.00 -1,220.00 5,214.00
2012-12-31 14,899.00 -1,706.00 4,577.00
2012-09-30 21,489.00 -1,302.00 7,567.00
2012-06-30 21,798.00 -1,013.00 7,827.00
2012-03-31 21,892.00 -1,303.00 7,985.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Pharmacy Chain 36.6 has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Pharmacy Chain 36.6 has efficiently used its assets last year compared to the Europe Consumer Retailing industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Pharmacy Chain 36.6 improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Pharmacy Chain 36.6's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Consumer Retailing industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Pharmacy Chain 36.6 has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

APTK Health

 How is Pharmacy Chain 36.6's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Pharmacy Chain 36.6's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Pharmacy Chain 36.6's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Pharmacy Chain 36.6's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Pharmacy Chain 36.6's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Pharmacy Chain 36.6 has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Pharmacy Chain 36.6 Company Filings, last reported 8 months ago.

MISX:APTK Past Debt and Equity Data
Date (Data in RUB Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 -18,885.00 39,722.00 714.00
2018-03-31 -18,885.00 39,722.00 714.00
2017-12-31 -13,818.00 32,173.00 659.00
2017-09-30 -13,818.00 32,173.00 659.00
2017-06-30 26.00 26,500.00 316.00
2017-03-31 26.00 26,500.00 316.00
2016-12-31 -531.00 20,292.00 585.00
2016-09-30 -531.00 20,292.00 585.00
2016-06-30 3,834.00 15,841.00 297.00
2016-03-31 3,834.00 15,841.00 297.00
2015-12-31 1,387.00 13,207.00 284.00
2015-06-30 3,125.00 10,474.00 728.00
2015-03-31 3,125.00 10,474.00 728.00
2014-12-31 242.00 12,457.00 392.00
2014-06-30 -11,051.00 9,606.00 222.00
2014-03-31 -11,051.00 9,606.00 222.00
2013-12-31 -10,309.00 8,549.00 489.00
2013-06-30 2,748.00 12,159.00 719.00
2013-03-31 3,549.00 10,385.00 436.00
2012-12-31 3,674.00 10,910.00 838.00
2012-09-30 3,548.00 11,142.00 1,711.00
2012-06-30 3,866.00 9,912.00 1,141.00
2012-03-31 4,200.00 9,676.00 948.00
  • Pharmacy Chain 36.6 has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Pharmacy Chain 36.6's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Pharmacy Chain 36.6 has less than a year of cash runway based on current free cash flow.
  • Pharmacy Chain 36.6 has less than a year of cash runway if free cash flow continues to grow at historical rates of 81.9% each year.
X
Financial health checks
We assess Pharmacy Chain 36.6's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Pharmacy Chain 36.6 has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

APTK Dividends

 What is Pharmacy Chain 36.6's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Pharmacy Chain 36.6 dividends.
If you bought RUB2,000 of Pharmacy Chain 36.6 shares you are expected to receive RUB0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Pharmacy Chain 36.6's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Pharmacy Chain 36.6's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
MISX:APTK Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Consumer Retailing Industry Average Dividend Yield Market Cap Weighted Average of 33 Stocks 3.4%
Russian Federation Market Average Dividend Yield Market Cap Weighted Average of 72 Stocks 6.2%
Russian Federation Minimum Threshold Dividend Yield 10th Percentile 1.5%
Russian Federation Bottom 25% Dividend Yield 25th Percentile 3.1%
Russian Federation Top 25% Dividend Yield 75th Percentile 9.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Pharmacy Chain 36.6 has not reported any payouts.
  • Unable to verify if Pharmacy Chain 36.6's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Pharmacy Chain 36.6's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Pharmacy Chain 36.6 has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Pharmacy Chain 36.6's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Pharmacy Chain 36.6 afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Pharmacy Chain 36.6 has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

APTK Management

 What is the CEO of Pharmacy Chain 36.6's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Vladimir Kintsurashvili
AGE 51
CEO Bio

Mr. Vladimir Vazhaevich Kintsurashvili serves as General Director & Chairman of the Management Board at Open Joint Stock Company Pharmacy Chain 36.6. Mr. Kintsurashvili served as a General Manager of Open Joint Stock Company Pharmacy Chain 36.6 and served as its Director since November 27, 2013. Mr. Kintsurashvili is the Co-Owner of LLC Apteka A.V.E. Mr. Kintsurashvili headed the pharmacy chain A5 (OJSC TS Aptechka) from 2006 to 2011. He was released from the post in 2011. After he left A5, he and partner Ivan Saganelidze began to develop their own pharmacy chain, A.v.e., which was set up initially with twenty outlets under the brand name Alphega. In September 2012, A.v.e. joined up with the Moscow-based discounter Gorzdrav. Gorzdrav's owners, Igor Zhibarovsky and Temur Shakaya, obtained 45% of A.v.e. in equal proportions. He

CEO Compensation
  • Insufficient data for Vladimir to compare compensation growth.
  • Insufficient data for Vladimir to establish whether their remuneration is reasonable compared to companies of similar size in .
Management Team

Vladimir Kintsurashvili

TITLE
General Director & Chairman of the Management Board
AGE
51

Bicherkharov Ramazanovich

TITLE
General Director & Member of the Management Board
AGE
37

Ivan Saganelidze

TITLE
First Deputy General Director
AGE
50

Ekaterina Esinevich

TITLE
Chief Financial Officer

Ruslan Nasybullin

TITLE
Chief Operational Officer

Gusarov Igorevich

TITLE
Director of Corporate Finance & Member of the Management Board
AGE
41

Fogel Henriys

TITLE
Member of the Management Board
AGE
55

Deryabina Anatolyevna

TITLE
Member of the Management Board
AGE
46

Kherianov Tamazovich

TITLE
Member of the Management Board
AGE
45

Prokhorenko Yuryevich

TITLE
Member of the Management Board
AGE
33
Board of Directors

Sergey Yuryevich

TITLE
Director
AGE
45

Kirilkin Sergeyevich

TITLE
Director
AGE
32

Aleksey Abolyayev

TITLE
Director

Vladimir Nesterenko

TITLE
Director

Oksana Tarasova

TITLE
Director

Oleg Fatuyev

TITLE
Director

Pavel Shadrin

TITLE
Director

Svetlana Afonchenko

TITLE
Member of Audit Commission

Olga Korsunskaya

TITLE
Member of Audit Commission

Ilya Levin

TITLE
Member of Audit Commission
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (RUB) Value (RUB)
X
Management checks
We assess Pharmacy Chain 36.6's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Pharmacy Chain 36.6 has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

APTK News

Simply Wall St News

Should You Be Concerned About Public Joint-Stock Company Pharmacy Chain 366's (MCX:APTK) Shareholders?

In this article, I'm going to take a look at Public Joint-Stock Company Pharmacy Chain 366’s (MISX:APTK) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … Private Company Ownership Potential investors in APTK should also look at another important group of investors: private companies, with a stake of 68.93%, who are primarily invested because of strategic and capital gain interests. … Thus, potential investors should look into these business relations and check how it can impact long-term shareholder returns.Next Steps: Institutional ownership level and composition in APTK is not high nor active enough to significantly impact its investment thesis.

Simply Wall St -

Does Public Joint-Stock Company Pharmacy Chain 366 (MCX:APTK) Have Enough Money Left To Grow?

Pharmacy Chain 36.6 may need to come to market again, but the question is, when? … View our latest analysis for Pharmacy Chain 36.6 What is cash burn? … MISX:APTK Income Statement Apr 24th 18 When will Pharmacy Chain 36.6 need to raise more cash?

Simply Wall St -

What Investors Should Know About Public Joint-Stock Company Pharmacy Chain 366's (MCX:APTK) Financial Strength

With this increase in debt, APTK currently has RUРУБ585.00M remaining in cash and short-term investments for investing into the business. … Moving onto cash from operations, its small level of operating cash flow means calculating cash-to-debt wouldn't be too useful, though these low levels of cash means that operational efficiency is worth a look. … Maintaining a high level of debt, while revenues are still below costs, can be dangerous as liquidity tends to dry up in unexpected downturns.Next Steps: With a high level of debt on its balance sheet, APTK could still be in a financially strong position if its cash flow also stacked up.

Simply Wall St -

APTK Company Info

Description

Public Joint-Stock Company Pharmacy Chain 36.6 operates pharmacies in Russia. Its pharmacies offer approximately 30 categories of goods for health and beauty. As of December 31, 2017, it operated 1601 pharmacies under the 36.6 brand name in the regions of Moscow, St. Petersburg, and Leningrad. The company was founded in 1991 and is based in Moscow, Russia.

Details
Name: Public Joint-Stock Company Pharmacy Chain 36.6
APTK
Exchange: MISX
Founded: 1991
RUB11,746,462,119
2,330,647,246
Website: http://pharmacychain366.ru
Address: Public Joint-Stock Company Pharmacy Chain 36.6
st. Vasilisa Kozhina, 1,
Moscow,
121096,
Russia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
MISX APTK Ordinary Shares Micex - Rts RU RUB 04. Feb 2004
Number of employees
Current staff
Staff numbers
0
Pharmacy Chain 36.6 employees.
Industry
Drug Retail
Consumer Retailing
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/23 21:19
End of day share price update: 2019/03/22 00:00
Last earnings filing: 2018/08/29
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.